Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Change (functional) | = -38 % | Antiinflammatory activity by rat adjuvant arthritis assay at 30 mg/kg peroral administration (3h edema). | ChEMBL. | 7739006 |
Change (functional) | = -36 % | Antiinflammatory activity by rat Carrageenan edema assay at 50 mg/kg peroral administration (3h edema). | ChEMBL. | 7739006 |
Change (binding) | = -23 % | Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 microM. | ChEMBL. | 7739006 |
Change (binding) | = -23 % | Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 microM. | ChEMBL. | 7739006 |
Change (binding) | = -18 % | Inhibition of prostaglandin G/H synthase pathway in rat polymorphonuclear assay by ability to inhibit formation of TXB2 at 10 uM. | ChEMBL. | 7739006 |
Change (binding) | = -18 % | Inhibition of prostaglandin G/H synthase pathway in rat polymorphonuclear assay by ability to inhibit formation of TXB2 at 10 uM. | ChEMBL. | 7739006 |
Change (binding) | = -15 % | Inhibition of Prostaglandin G/H synthase pathway in rat polymorphonuclear assay by ability to inhibit formation of PGE-2 at 10 microM. | ChEMBL. | 7739006 |
Change (binding) | = -15 % | Inhibition of Prostaglandin G/H synthase pathway in rat polymorphonuclear assay by ability to inhibit formation of PGE-2 at 10 microM. | ChEMBL. | 7739006 |
Change (binding) | = -5 % | 5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE | ChEMBL. | 7739006 |
Change (binding) | = -5 % | 5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE | ChEMBL. | 7739006 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.